Use of eculizumab in the treatment of a case of refractory, adamts13-deficient thrombotic thrombocytopenic purpura: Additional data and clinical follow-up

British Journal of Haematology

Volumn 162, Issue 4, 2013, Pages 558-559

  Tsai, Eugenia ^a   Chapin, John ^b   Laurence, Jeffrey C ^b   Tsai, Han Mou ^c  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c E DA HOSPITAL   (Taiwan)

Author keywords

antibodies; atypical haemolytic uraemic syndrome; complement factor h; Thrombotic thrombocytopenic purpura

Indexed keywords

COMPLEMENT FACTOR H; COMPLEMENT FACTOR H ANTIBODY; ECULIZUMAB; GLUCOCORTICOID; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY DETECTION; ANTIBODY TITER; CLINICAL EXAMINATION; COMPLEMENT FACTOR H GENE; DRUG APPROVAL; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LETTER; NEUROLOGIC DISEASE; OPTICAL DENSITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; THERAPY RESISTANCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES; ATYPICAL HAEMOLYTIC URAEMIC SYNDROME; COMPLEMENT FACTOR H; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84880700770     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12387     Document Type: Letter

References (6)

1. Chapin, J., Weksler, B., Magro, C. & Laurence, J. (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157, 772-774.
2. Dragon-Durey, M.A., Loirat, C., Cloarec, S., Macher, M.A., Blouin, J., Nivet, H., Weiss, L., Fridman, W.H. & Fremeaux-Bacchi, V. (2005) Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology, 16, 555-563.
3. Dragon-Durey, M.A., Sethi, S.K., Bagga, A., Blanc, C., Blouin, J., Ranchin, B., Andre, J.L., Takagi, N., Cheong, H.I., Hari, P., Le, Q.M., Niaudet, P., Loirat, C., Fridman, W.H. & Fremeaux-Bacchi, V. (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. Journal of the American Society of Nephrology, 21, 2180-2187.
4. Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, J.D. Jr, Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488-494.
5. Maga, T.K., Nishimura, C.J., Weaver, A.E., Frees, K.L. & Smith, R.J. (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Human Mutation, 31, E1445-E1460.
6. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 339, 1585-1594.